

1. October

Heidelberg
& digital

Novel therapeutics:
Biotechnology
leading the way into the future



AGENDA

08:30 Registration & Dial-in

09:00 **Welcome & Introduction**

09:15 Keynote: "Next generation Immunotherapy"

Holger Kissel, BioNTech SE, Vice President Business Alliances

Dirk Grimm, University of Heidelberg, Professor and Group Leader

"The fast and the curious – high-throughput in vitro and in vivo interrogation of AAV capsid libraries"

09:50 **Christiane Kofink, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Principal Scientist**

"The discovery of the first selective and orally bioavailable SMARCA2 degrader BI-0284"

10:30 Break & Poster Session

Ivan Đikić, Goethe University Frankfurt, Professor

"PROXIDRUGS: new therapeutic options for numerous diseases"

11:00 **Claus Kremoser, WMT Therapeutics AG, Co-Founder and Chairman of the Board**

"Targeting Cancer Metabolism to foster Immune Attack on Solid Tumours"

Michael Zimmermann, EMBL, Group Leader

"Identifying microbiome contributions to drug metabolism and toxicity"

12:00 Lunch, Networking & Poster Session

13:00 – 14:00 **Parallel Workshops**

“Futureproofing your Process Development” by Cytiva.

You will learn about novel downstream solutions tailored for ATMPs and the impact on Process Development. Plus, how Mechanistic modelling can Improve process understanding and performance for novel therapies

[more >>](#)

“Innovative technologies and statistical methods for successful drug development” by Cytel.

Explore technological solutions which enables cross-functional teams to optimize speed, cost and probability of success in drug development. And discover which Bayesian approaches can be used from preclinical to post-authorization to support orphan drug development.

[more >>](#)

“Emerging Biotechnology Venture Capital” by M Ventures

Discuss the state of the Biotechnology funding and investing landscape and explore how the recent pandemic has boosted investor interest in innovative biotech startups and driven the sector beyond its already strong projections.

[more >>](#)

14:10

Keynote: “Development of Bulevirtide/Hepcludex®, the first approved medication to treat chronic Hepatitis D infections.”

Stephan Urban, Heidelberg University Hospital, Head of the Translational Virology Unit

14:40

Thomas Hanke, Evotec, EVP Head of Academic Partnerships

“Building BRIDGES across the Rhine, Main, Neckar and other rivers”

15:00

Happy Hour & Speed-Networking

17:00

Closing

[More & Registration](#)

Sponsors



Conference Supporters

abbvie



MERCK

Key Public Partner



Workshop Partner

